HomeMarketsEarningsNVO Earnings In Focus: Weight Loss Drugs, Combatting Copy Cats

NVO Earnings In Focus: Weight Loss Drugs, Combatting Copy Cats

Kyle Bergacker joins Sam Vadas to discuss Novo Nordisk (NVO) earnings. Shares of the biotech pharmaceutical company are down following its 2Q report. Kyle discusses the lowered sales growth in its guidance as well as combatting "copy cat" medications from telehealth companies. He adds commentary on the company's GLP-1 weight loss drugs and what it means in regards to the long-term outlook for Novo Nordisk.

Morning Movers

06 Aug 2025

SHARE

ON AIR
education
6:00 am
Schwab 2026 Outlook
replay
education
12:00 am
Schwab 2026 Outlook
REPLAY
1:00 am
Market Overtime
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Market Overtime
REPLAY
4:30 am
Market Overtime
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
Market Overtime
REPLAY
ON AIR
education
6:00 am
Schwab 2026 Outlook
REPLAY
7:00 am
Market Overtime
REPLAY
education
8:00 am
Your First Trade
REPLAY
education
8:30 am
Your First Trade
REPLAY
9:00 am
Fast Market
REPLAY
10:00 am
Market Overtime
REPLAY
10:30 am
Market Overtime
REPLAY
11:00 am
Market Overtime
REPLAY
11:30 am
Market Overtime
REPLAY
education
12:00 pm
Schwab 2026 Outlook
REPLAY
1:00 pm
Market Overtime
REPLAY
education
2:00 pm
Your First Trade
REPLAY
education
2:30 pm
Your First Trade
REPLAY
3:00 pm
Fast Market
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market Overtime
REPLAY
5:00 pm
Market Overtime
REPLAY
5:30 pm
Market Overtime
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Market Overtime
REPLAY
education
8:00 pm
Your First Trade
REPLAY
education
8:30 pm
Your First Trade
REPLAY
9:00 pm
Fast Market
REPLAY
10:00 pm
Market Overtime
REPLAY
10:30 pm
Market Overtime
REPLAY
11:00 pm
Market Overtime
REPLAY
11:30 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor